{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T20:52:47Z","timestamp":1792270367741,"version":"4.4.0"},"reference-count":25,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2023,1,20]],"date-time":"2023-01-20T00:00:00Z","timestamp":1674172800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,8,31]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>The nephrotoxicity of bortezomib, a proteasome inhibitor, has not yet been elucidated, although tumor lysis syndrome (TLS) associated with multiple myeloma (MM) has been reported to increase after introduction of the drug. This study compared the incidence and risk factors for acute kidney injury (AKI) and TLS in patients with MM after bortezomib-based chemotherapy to investigate drug-related nephrotoxicity.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>From 2006 to 2017, 276 patients who underwent a first cycle of bortezomib-based chemotherapy for MM were identified in a single tertiary hospital. Laboratory TLS was defined according to the Cairo-Bishop definition. Development of AKI was assessed by AKI Network criteria within 7 days of the first chemotherapy.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>The median (interquartile range) age was 65 (56\u201372) years, and baseline estimated glomerular filtration rate (eGFR) was 61.3 (34.1\u201389.1) mL\/min\/1.73 m2. The incidences of AKI and laboratory TLS were 17% (n\u00a0=\u00a047) and 13% (n\u00a0=\u00a036), respectively. Ten (3.6%) subjects met both AKI and TLS criteria. Multivariate analyses showed that lower eGFR category [30\u201359, odds ratio (OR) 3.005 (95% confidence interval 1.163\u20137.976); 15\u201329, OR 4.225 (1.183\u201315.000); &amp;lt;15, OR 16.154 (3.831\u201370.920) vs \u226560, P\u00a0&amp;lt;\u00a0.001], lower serum albumin level [per 1 increase, OR 0.479 (0.256\u20130.871), P\u00a0=\u00a0.018], renal amyloidosis [OR 13.039 (4.108\u201344.041), P\u00a0&amp;lt;\u00a0.001] and use of acyclovir during bortezomib treatment [OR 3.689 (1.133\u201314.469), P\u00a0=\u00a0.042] were predictors of AKI. MM stages and \u03b2-2-microglobulin were not associated with increased risk of AKI. Regarding laboratory TLS, MM stage and \u03b2-2-microglobulin were higher in those with TLS than in others. In multivariate analyses, \u03b2-2-microglobulin level [OR 1.204 (1.005\u20131.461), P\u00a0=\u00a0.038] and absence of high-risk chromosome abnormalities [OR 0.143 (0.022\u20130.588), P\u00a0=\u00a0.016] were associated with higher risk of TLS.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Development of AKI was often observed in the absence of TLS in patients with MM after treatment with bortezomib. In addition, the risk factors for AKI and TLS varied widely. These findings indicate the potential nephrotoxicity of bortezomib irrespective of TLS in patients with decreased kidney function.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ndt\/gfad016","type":"journal-article","created":{"date-parts":[[2023,1,19]],"date-time":"2023-01-19T12:55:16Z","timestamp":1674132916000},"page":"2077-2085","source":"Crossref","is-referenced-by-count":13,"title":["Acute kidney injury in bortezomib-treated patients with multiple myeloma"],"prefix":"10.1093","volume":"38","author":[{"given":"Seung Min","family":"Song","sequence":"first","affiliation":[{"name":"Nephrology Division; Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine , Seoul , Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junseok","family":"Jeon","sequence":"additional","affiliation":[{"name":"Nephrology Division; Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine , Seoul , Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hye Ryoun","family":"Jang","sequence":"additional","affiliation":[{"name":"Nephrology Division; Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine , Seoul , Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kihyun","family":"Kim","sequence":"additional","affiliation":[{"name":"Hematology Division; Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine , Seoul , Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wooseong","family":"Huh","sequence":"additional","affiliation":[{"name":"Nephrology Division; Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine , Seoul , Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoon-Goo","family":"Kim","sequence":"additional","affiliation":[{"name":"Nephrology Division; Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine , Seoul , Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jung Eun","family":"Lee","sequence":"additional","affiliation":[{"name":"Nephrology Division; Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine , Seoul , Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,1,20]]},"reference":[{"key":"2023083104261681700_bib1","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.2215\/CJN.01640216","article-title":"American Society of Nephrology Onco-Nephrology Forum. Paraprotein-related kidney disease: evaluation and treatment of myeloma cast nephropathy","volume":"11","author":"Finkel","year":"2016","journal-title":"Clin J Am Soc Nephrol"},{"key":"2023083104261681700_bib2","first-page":"1","article-title":"Mechansim of action of bortezomib in multiple myeloma therapy","volume":"6","author":"Masaki","year":"2016","journal-title":"Int J Myeloma"},{"key":"2023083104261681700_bib3","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1159\/000442511","article-title":"Current trends of renal impairment in multiple myeloma","volume":"1","author":"Yadav","year":"2015","journal-title":"Kidney Dis"},{"key":"2023083104261681700_bib4","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1056\/NEJMra1613984","article-title":"Acute kidney injury in patients with cancer","volume":"376","author":"Rosner","year":"2017","journal-title":"N Engl J Med"},{"key":"2023083104261681700_bib5","first-page":"1225","article-title":"Bortezomib-induced acute interstitial nephritis","volume":"30","author":"Cheungpasitporn","year":"2015","journal-title":"Nephrol\u00a0Dial Transplant"},{"key":"2023083104261681700_bib6","doi-asserted-by":"crossref","first-page":"37","DOI":"10.4081\/hr.2012.e13","article-title":"Thrombotic microangiopathy associated with bortezomib treatment in a patient with relapsed multiple myeloma","volume":"4","author":"Salmenniemi","year":"2012","journal-title":"Hematol Rep"},{"key":"2023083104261681700_bib7","doi-asserted-by":"crossref","first-page":"176","DOI":"10.2215\/CJN.06100616","article-title":"Renal toxicities of novel agents used for treatment of multiple myeloma","volume":"12","author":"Wanchoo","year":"2017","journal-title":"Clin J Am Soc Nephrol"},{"key":"2023083104261681700_bib8","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1007\/s00277-015-2585-7","article-title":"Tumor lysis syndrome in the era of novel and targeted agents in patients with hematologic malignancies: a systematic review","volume":"95","author":"Howard","year":"2016","journal-title":"Ann Hematol"},{"key":"2023083104261681700_bib9","doi-asserted-by":"crossref","first-page":"233","DOI":"10.3816\/CLM.2006.n.064","article-title":"Bortezomib-induced tumor lysis syndrome in multiple myeloma","volume":"7","author":"Sezer","year":"2006","journal-title":"Clin Lymphoma Myeloma"},{"key":"2023083104261681700_bib10","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1007\/s00432-004-0593-4","article-title":"Tumour lysis syndrome in multiple myeloma after bortezomib (VELCADE) administration","volume":"130","author":"Terpos","year":"2004","journal-title":"J Cancer Res Clin Oncol"},{"key":"2023083104261681700_bib11","doi-asserted-by":"crossref","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","article-title":"A new equation to estimate glomerular filtration rate","volume":"150","author":"Levey","year":"2009","journal-title":"Ann Intern Med"},{"key":"2023083104261681700_bib12","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1002\/ajh.25791","article-title":"Multiple myeloma: 2020 update on diagnosis, risk-stratification and management","volume":"95","author":"Rajkumar","year":"2020","journal-title":"Am J Hematol"},{"key":"2023083104261681700_bib13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/cc5713","article-title":"Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury","volume":"11","author":"Mehta","year":"2007","journal-title":"Crit Care"},{"key":"2023083104261681700_bib14","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.1365-2141.2004.05094.x","article-title":"Tumour lysis syndrome: new therapeutic strategies and classification","volume":"127","author":"Cairo","year":"2004","journal-title":"Br J Haematol"},{"key":"2023083104261681700_bib15","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.ekir.2016.06.002","article-title":"Acute tubular necrosis in a patient with myeloma treated with carfilzomib","volume":"1","author":"Liberman","year":"2016","journal-title":"Kidney Int Rep"},{"key":"2023083104261681700_bib16","doi-asserted-by":"crossref","first-page":"F451","DOI":"10.1152\/ajprenal.90576.2008","article-title":"The proteasome inhibitor bortezomib aggravates renal ischemia-reperfusion injury","volume":"297","author":"Huber","year":"2009","journal-title":"Am J Physiol Renal Physiol"},{"key":"2023083104261681700_bib17","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1053\/ajkd.2000.17620","article-title":"Cytotoxicity of myeloma light chains in cultured human kidney proximal tubule cells","volume":"36","author":"Pote","year":"2000","journal-title":"Am J Kidney Dis"},{"key":"2023083104261681700_bib18","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.2215\/CJN.02050309","article-title":"Renal vulnerability to drug toxicity","volume":"4","author":"Perazella","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"key":"2023083104261681700_bib19","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/S0002-9343(99)00041-8","article-title":"Crystal-induced acute renal failure","volume":"106","author":"Perazella","year":"1999","journal-title":"Am J Med"},{"key":"2023083104261681700_bib20","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1002\/cncr.24006","article-title":"Acyclovir to prevent reactivation of varicella zoster virus (herpes zoster) in multiple myeloma patients receiving bortezomib therapy","volume":"115","author":"Vickrey","year":"2009","journal-title":"Cancer"},{"key":"2023083104261681700_bib21","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1093\/jjco\/hyq194","article-title":"Low-dose acyclovir is effective for prevention of herpes zoster in myeloma patients treated with bortezomib: a report from the Korean Multiple Myeloma Working Party (KMMWP) Retrospective Study","volume":"41","author":"Kim","year":"2011","journal-title":"Jpn J Clin Oncol"},{"key":"2023083104261681700_bib22","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1053\/j.seminhematol.2009.01.005","article-title":"Management of complications in multiple myeloma","volume":"46","author":"Terpos","year":"2009","journal-title":"Semin Hematol"},{"key":"2023083104261681700_bib23","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/j.beha.2007.08.001","article-title":"Epidemiology of the plasma-cell disorders","volume":"20","author":"Kyle","year":"2007","journal-title":"Best Pract Res Clin Haematol"},{"key":"2023083104261681700_bib24","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1056\/NEJMra023144","article-title":"Molecular mechanisms of amyloidosis","volume":"349","author":"Merlini","year":"2003","journal-title":"N Engl J Med"},{"key":"2023083104261681700_bib25","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1111\/bjh.12269","article-title":"The prognostic value of diagnosing concurrent multiple myeloma in immunoglobulin light chain amyloidosis","volume":"161","author":"Dinner","year":"2013","journal-title":"Br J Haematol"}],"container-title":["Nephrology Dialysis Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ndt\/advance-article-pdf\/doi\/10.1093\/ndt\/gfad016\/49880963\/gfad016.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ndt\/article-pdf\/38\/9\/2077\/51277654\/gfad016.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ndt\/article-pdf\/38\/9\/2077\/51277654\/gfad016.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,31]],"date-time":"2023-08-31T04:52:54Z","timestamp":1693457574000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ndt\/article\/38\/9\/2077\/6994382"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,20]]},"references-count":25,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2023,1,20]]},"published-print":{"date-parts":[[2023,8,31]]}},"URL":"https:\/\/doi.org\/10.1093\/ndt\/gfad016","relation":{},"ISSN":["0931-0509","1460-2385"],"issn-type":[{"value":"0931-0509","type":"print"},{"value":"1460-2385","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,9]]},"published":{"date-parts":[[2023,1,20]]}}}